Home LiteratureArticle Details
PMID: 17579625 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.

British journal of cancer ·Vol. 97 ·No. 2 ·2007-07-16 ·Pages 231-7

Fojtova M, Boudny V, Kovarik A, Lauerova L, Adamkova L, Souckova K, Jarkovsky J, Kovarik J

Abstract

The resistance to interferons (IFNs) limits their anticancer therapeutic efficacy. Here we studied the evolution of an IFN-resistant state in vitro using melanoma cell lines. We found that the cells became less sensitive to antiproliferative effect of IFN-gamma after prolonged cultivation enabling us to isolate sensitive and resistant subclones of the parental line. We investigated transcription of signal transducer and activator of transcription (STAT) 1-6 and suppressor of cytokine signalling (SOCS) 1-3 genes, and phosphorylation of STAT 1 protein. The resistant subline (termed WM 1158R) differed from the sensitive subline (WM 1158S) by a constitutive expression of SOCS 3, lack or weak SOCS 1-3 activation following IFN-gamma, and short duration of cytokine activatory signal. Similar correlations were observed in additional melanoma lines differing in IFN sensitivities. At the protein level, IFN-gamma induced strong and prolonged STAT 1 activation at serine 727 (S727) in WM 1158R while in WM 1158S cells phosphorylation of this amino acid was much less pronounced. On the other hand, phosphorylation of tyrosine 701 (Y701) was stimulated regardless of the sensitivity phenotype. In conclusion, constitutive expression of SOCS 3 is correlated with attenuation of its induction following IFN treatment. These results suggest that progression of melanoma cells from IFN sensitivity to IFN insensitivity associates with changes in SOCS expression.

MeSH Terms
Cell Line, Tumor Cell Proliferation/drug effects Drug Resistance, Neoplasm/genetics Gene Expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Interferon-gamma/pharmacology,therapeutic use Melanoma/drug therapy,genetics Phosphorylation STAT1 Transcription Factor/metabolism Skin Neoplasms/drug therapy,genetics Suppressor of Cytokine Signaling 3 Protein Suppressor of Cytokine Signaling Proteins/genetics
Chemicals
SOCS3 protein, human STAT1 Transcription Factor STAT1 protein, human Suppressor of Cytokine Signaling 3 Protein Suppressor of Cytokine Signaling Proteins Interferon-gamma
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Fojtova M
Institute of Biophysics, Academy of Sciences of the Czech Republic v.v.i., Kralovopolska 135, 612 65 Brno, Czech Republic.
Boudny V
Kovarik A
Lauerova L
Adamkova L
Souckova K
Jarkovsky J
Kovarik J
References (37)
37 references, click to expand
  1. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.
    Blood. 2002 Oct 15;100(8):2926-31 PMID: 12351404
  2. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
    J Immunol. 2002 Jul 15;169(2):847-55 PMID: 12097388
  3. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation.
    Int J Mol Med. 2003 Sep;12(3):335-40 PMID: 12883649
  4. Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients.
    Folia Biol (Praha). 2003;49(4):142-6 PMID: 12971583
  5. STAT proteins: from normal control of cellular events to tumorigenesis.
    J Cell Physiol. 2003 Nov;197(2):157-68 PMID: 14502555
  6. Epigenetic switch from posttranscriptional to transcriptional silencing is correlated with promoter hypermethylation.
    Plant Physiol. 2003 Nov;133(3):1240-50 PMID: 14551338
  7. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 PMID: 14617776
  8. Regulation of cytokine signaling by SOCS family molecules.
    Trends Immunol. 2003 Dec;24(12):659-66 PMID: 14644140
  9. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals.
    J Invest Dermatol. 2004 Feb;122(2):414-22 PMID: 15009724
  10. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers.
    Jpn J Clin Oncol. 2004 Apr;34(4):191-4 PMID: 15121754
  11. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.
    J Invest Dermatol. 2004 Oct;123(4):737-45 PMID: 15373779
  12. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.
    Oncogene. 2004 Oct 7;23(46):7726-33 PMID: 15361843
  13. Analysis of the tissue-specific promoter of the MUC1 gene.
    J Biol Chem. 1993 May 5;268(13):9917-26 PMID: 8387509
  14. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
    Cancer Res. 1993 Jun 15;53(12):2708-11 PMID: 8504408
  15. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins.
    Nature. 1993 Dec 9;366(6455):580-3 PMID: 7504784
  16. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
    Cell. 1996 Feb 9;84(3):443-50 PMID: 8608598
  17. Cloning and characterization of novel CIS family genes.
    Biochem Biophys Res Commun. 1997 Oct 20;239(2):439-46 PMID: 9344848
  18. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.
    J Biol Chem. 1997 Nov 7;272(45):28779-85 PMID: 9353349
  19. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm.
    N Engl J Med. 1998 Feb 26;338(9):616-8 PMID: 9475772
  20. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine.
    Cell. 1999 Sep 3;98(5):597-608 PMID: 10490099
  21. Negative regulators of cytokine signal transduction.
    Cell Mol Life Sci. 1999 Sep;55(12):1568-77 PMID: 10526574
  22. Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells.
    FEBS Lett. 1999 Oct 15;459(3):323-6 PMID: 10526158
  23. SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells.
    Mol Immunol. 2005 Feb;42(3):295-303 PMID: 15589317
  24. Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts.
    Biochem Biophys Res Commun. 2005 Feb 18;327(3):727-33 PMID: 15649407
  25. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
    Cancer Immunol Immunother. 2005 Sep;54(9):815-25 PMID: 15668815
  26. STAT5 contributes to interferon resistance of melanoma cells.
    Curr Biol. 2005 Sep 20;15(18):1629-39 PMID: 16169484
  27. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition.
    Oncogene. 2005 Oct 6;24(44):6699-708 PMID: 16007169
  28. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines.
    Melanoma Res. 2005 Dec;15(6):481-8 PMID: 16314732
  29. Stats: multifaceted regulators of transcription.
    J Interferon Cytokine Res. 2005 Dec;25(12):733-44 PMID: 16375601
  30. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis.
    Oncogene. 2006 Dec 7;25(58):7555-64 PMID: 16799645
  31. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.
    Oncogene. 2007 Mar 22;26(13):1941-8 PMID: 17001312
  32. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.
    Int J Cancer. 2000 Mar 1;85(5):720-5 PMID: 10699955
  33. Clonal selection versus genetic instability as the driving force in neoplastic transformation.
    Cancer Res. 2000 Nov 15;60(22):6510-8 PMID: 11103821
  34. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression.
    EMBO J. 2001 Jan 15;20(1-2):91-100 PMID: 11226159
  35. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
    Nat Genet. 2001 May;28(1):29-35 PMID: 11326271
  36. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
    J Clin Oncol. 2002 Apr 1;20(7):1818-25 PMID: 11919239
  37. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line.
    Melanoma Res. 2003 Jun;13(3):219-29 PMID: 12777975
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2007-07-16
Epub
2007-00-19
Pages
231-7
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2360293
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com